Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa C Toffoli

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cell Reports. Medicine|October 14, 2025
Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulationGeorgia Clayton, Elisa C Toffoli, Tanja D de Gruijl, et al.
Journal for Immunotherapy of Cancer|December 6, 2023
Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancerElisa C Toffoli, Amanda A van Vliet, Henk W M Verheul, et al.
Physiological Reports|June 10, 2021
Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot studyElisa C Toffoli, Maike G Sweegers, Hetty J Bontkes, et al.
Cancers|February 12, 2021
Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic ResponseElisa C Toffoli, Abdolkarim Sheikhi, Yannick D Höppner, et al.
Cancers|November 13, 2021
Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor ReceptorElisa C Toffoli, Abdolkarim Sheikhi, Roeland Lameris, et al.
BMC Cancer|November 10, 2019
Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatinMaurice J D L van der Vorst, Elisabeth C W Neefjes, Elisa C Toffoli, et al.
Oncoimmunology|May 7, 2026
Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanomaJessica C L Notohardjo, Elisa C Toffoli, Tara Muijlwijk, et al.
The Oncologist|August 1, 2020
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority TrialMaurice J D L van der Vorst, Elisa C Toffoli, Marlien Beusink, et al.
Cancer Immunology Research|June 27, 2023
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing TumorsLisa A King, Elisa C Toffoli, Myrthe Veth, et al.
European Journal of Immunology|December 13, 2024
Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DCDiana Dudziak, Lukas Heger, William W Agace, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cell Reports. Medicine|October 14, 2025
Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulationGeorgia Clayton, Elisa C Toffoli, Tanja D de Gruijl, et al.
Journal for Immunotherapy of Cancer|December 6, 2023
Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancerElisa C Toffoli, Amanda A van Vliet, Henk W M Verheul, et al.
Physiological Reports|June 10, 2021
Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot studyElisa C Toffoli, Maike G Sweegers, Hetty J Bontkes, et al.
Cancers|February 12, 2021
Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic ResponseElisa C Toffoli, Abdolkarim Sheikhi, Yannick D Höppner, et al.
Cancers|November 13, 2021
Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor ReceptorElisa C Toffoli, Abdolkarim Sheikhi, Roeland Lameris, et al.
BMC Cancer|November 10, 2019
Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatinMaurice J D L van der Vorst, Elisabeth C W Neefjes, Elisa C Toffoli, et al.
Oncoimmunology|May 7, 2026
Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanomaJessica C L Notohardjo, Elisa C Toffoli, Tara Muijlwijk, et al.
The Oncologist|August 1, 2020
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority TrialMaurice J D L van der Vorst, Elisa C Toffoli, Marlien Beusink, et al.
Cancer Immunology Research|June 27, 2023
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing TumorsLisa A King, Elisa C Toffoli, Myrthe Veth, et al.
European Journal of Immunology|December 13, 2024
Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DCDiana Dudziak, Lukas Heger, William W Agace, et al.
Pageof 1